Trial Outcomes & Findings for Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies (NCT NCT03248479)
NCT ID: NCT03248479
Last Updated: 2025-01-17
Results Overview
TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and before the first date of new anti-cancer therapy including stem-cell transplant (SCT) and/or any AEs leading to premature discontinuation of study drug.
Recruitment status
TERMINATED
Study phase
PHASE1
Target enrollment
258 participants
Primary outcome timeframe
Up to 4 years
Results posted on
2025-01-17
Participant Flow
Participants were enrolled at study sites in the United States and the United Kingdom. 1 participant with low-risk MDS was accidentally enrolled High-risk MDS group.
258 participants were screened.
Participant milestones
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days).
Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002), or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days).
Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days).
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
32
|
63
|
1
|
87
|
19
|
6
|
1
|
17
|
5
|
10
|
9
|
5
|
3
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
32
|
63
|
1
|
87
|
19
|
6
|
1
|
17
|
5
|
10
|
9
|
5
|
3
|
Reasons for withdrawal
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days).
Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002), or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days).
Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days).
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Death
|
12
|
44
|
1
|
72
|
17
|
6
|
1
|
14
|
3
|
7
|
3
|
1
|
1
|
|
Overall Study
Study terminated by sponsor
|
12
|
15
|
0
|
5
|
0
|
0
|
0
|
1
|
1
|
0
|
5
|
4
|
0
|
|
Overall Study
Consent withdrawn
|
6
|
3
|
0
|
9
|
1
|
0
|
0
|
1
|
0
|
3
|
1
|
0
|
1
|
|
Overall Study
Lost to Follow-up
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Not reported
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
Baseline Characteristics
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Baseline characteristics by cohort
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=1 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=87 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=19 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=6 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
n=1 Participants
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002), or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
n=17 Participants
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=5 Participants
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days).
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab
n=10 Participants
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
n=9 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=5 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab
n=3 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day
1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Total
n=258 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
00 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
12 Participants
n=5 Participants
|
22 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
17 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
58 Participants
n=36 Participants
|
|
Age, Categorical
>=65 years
|
20 Participants
n=5 Participants
|
41 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
70 Participants
n=4 Participants
|
16 Participants
n=21 Participants
|
6 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
15 Participants
n=24 Participants
|
5 Participants
n=42 Participants
|
9 Participants
n=42 Participants
|
8 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
200 Participants
n=36 Participants
|
|
Age, Continuous
|
67 years
STANDARD_DEVIATION 9.1 • n=5 Participants
|
67 years
STANDARD_DEVIATION 11.6 • n=7 Participants
|
66 years
STANDARD_DEVIATION NA • n=5 Participants
|
71 years
STANDARD_DEVIATION 10.0 • n=4 Participants
|
73 years
STANDARD_DEVIATION 7.4 • n=21 Participants
|
77 years
STANDARD_DEVIATION 6.3 • n=8 Participants
|
79 years
STANDARD_DEVIATION NA • n=8 Participants
|
72 years
STANDARD_DEVIATION 7.2 • n=24 Participants
|
77 years
STANDARD_DEVIATION 1.7 • n=42 Participants
|
73 years
STANDARD_DEVIATION 5.3 • n=42 Participants
|
75 years
STANDARD_DEVIATION 5.9 • n=42 Participants
|
74 years
STANDARD_DEVIATION 7.7 • n=42 Participants
|
79 years
STANDARD_DEVIATION 6.4 • n=36 Participants
|
70 years
STANDARD_DEVIATION 9.8 • n=36 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=5 Participants
|
24 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
37 Participants
n=4 Participants
|
5 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
1 Participants
n=36 Participants
|
100 Participants
n=36 Participants
|
|
Sex: Female, Male
Male
|
23 Participants
n=5 Participants
|
39 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
50 Participants
n=4 Participants
|
14 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
12 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
7 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
2 Participants
n=36 Participants
|
158 Participants
n=36 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
17 Participants
n=36 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
29 Participants
n=5 Participants
|
54 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
81 Participants
n=4 Participants
|
18 Participants
n=21 Participants
|
6 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
14 Participants
n=24 Participants
|
5 Participants
n=42 Participants
|
9 Participants
n=42 Participants
|
8 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
233 Participants
n=36 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
8 Participants
n=36 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
8 Participants
n=36 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
11 Participants
n=36 Participants
|
|
Race (NIH/OMB)
White
|
31 Participants
n=5 Participants
|
54 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
75 Participants
n=4 Participants
|
15 Participants
n=21 Participants
|
5 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
16 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
10 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
225 Participants
n=36 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
13 Participants
n=36 Participants
|
|
Region of Enrollment
United States
|
31 Participants
n=5 Participants
|
63 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
85 Participants
n=4 Participants
|
19 Participants
n=21 Participants
|
6 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
17 Participants
n=24 Participants
|
5 Participants
n=42 Participants
|
10 Participants
n=42 Participants
|
8 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
253 Participants
n=36 Participants
|
|
Region of Enrollment
United Kingdom
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
5 Participants
n=36 Participants
|
PRIMARY outcome
Timeframe: Up to 4 yearsPopulation: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and before the first date of new anti-cancer therapy including stem-cell transplant (SCT) and/or any AEs leading to premature discontinuation of study drug.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=1 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=87 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=19 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=6 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
n=1 Participants
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
n=17 Participants
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=5 Participants
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
n=10 Participants
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
n=9 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=5 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
n=3 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
|
100 percentage of participants
|
96.8 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
100 percentage of participants
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to 5 yearsPopulation: Full Analysis Set included participants with AML who received ≥1 dose of magrolimab. As per the pre-specified analysis, this outcome measure was applicable only for the AML cohorts.
The CR rate is the percentage of participants who achieved CR without minimal residual disease (CRMRD-), and CR as per European Leukemia Net (ELN) AML recommendations. CRMRD- per ELN was defined as neutrophils ≥1.0 × 10\^9/L; platelets ≥100 × 10\^9/L and \<5% bone marrow blasts. If studied pretreatment, CR with negativity for a genetic marker by real-time quantitative polymerase chain reaction (RT-qPCR) or similar modality or CR with negativity by multi-color flow cytometry. CR per ELN criteria is defined as neutrophils ≥1.0 × 10\^9/L; platelets ≥100 × 10\^9/L and \<5% bone marrow blasts. Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; MRD positive or unknown.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=87 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=19 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=6 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=1 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Complete Remission (CR) Rate For Participants With AML
|
32.2 percentage of participants
Interval 22.6 to 43.1
|
0.0 percentage of participants
Interval 0.0 to 17.6
|
0.0 percentage of participants
Interval 0.0 to 45.9
|
0.0 percentage of participants
Interval 0.0 to 97.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to 5 yearsPopulation: Full Analysis Set included participants with MDS who received ≥1 dose of magrolimab. As per the pre-specified analysis, this outcome measure was applicable only for the MDS cohorts. For the TN MDS Cohort, only participants with higher MDS risk were included for the analyses of this outcome measure.
The CR rate was the percentage of MDS participants who achieved CR per International Working Group (IWG) 2006 criteria. CR per IWG criteria is defined as bone marrow ≤5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood should have: Hemoglobin (Hgb) ≥11 g/dL, platelets ≥100 × 10\^9/L, neutrophils ≥1.0 × 10\^9/L and blasts 0%.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=17 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=5 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=10 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=9 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
n=5 Participants
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
n=3 Participants
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CR Rate for Participants With MDS
|
37.5 percentage of participants
Interval 21.1 to 56.3
|
30.2 percentage of participants
Interval 19.2 to 43.0
|
0.0 percentage of participants
Interval 0.0 to 19.5
|
0.0 percentage of participants
Interval 0.0 to 52.2
|
0.0 percentage of participants
Interval 0.0 to 30.8
|
11.1 percentage of participants
Interval 0.3 to 48.2
|
0.0 percentage of participants
Interval 0.0 to 52.2
|
0.0 percentage of participants
Interval 0.0 to 70.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to 8 weeksPopulation: Full Analysis Set included participants with low-risk MDS who received ≥1 dose of magrolimab. As per the pre-specified analysis, this outcome measure was applicable only for the low risk MDS cohorts.
RBC transfusion independence was defined by the lack of RBC transfusions for at least an 8 week consecutive period at any time after starting therapy.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=9 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=5 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=3 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Red Blood Cell (RBC) Transfusion Independence for Participants With Low-Risk MDS
|
44.4 percentage of participants
Interval 13.7 to 78.8
|
40.0 percentage of participants
Interval 5.3 to 85.3
|
0.0 percentage of participants
Interval 0.0 to 70.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Predose and/or after 1 hour of infusion (duration 3 hours (± 30 minutes) for 1mg/kg; 2 hours for 15 mg/kg, 30 mg/kg and 60 mg/kg) in Cycles (each cycle of 28 days) 1 to 7, 9, 11, 13, 15, on Days 1, 2, 3, 4, 8, 11, 15, 16, 17, 18, 22, EOT, Safety Follow-upPopulation: The Pharmacokinetic (PK) Analysis Set included participants in All Enrolled Analysis Set, who took at least 1 dose of magrolimab and had at least 1 detectable postdose magrolimab concentration value reported by the PK laboratory at the given timepoint. As per the pre-specified analysis, this outcome measure was applicable only for the TN/U AML and TN MDS cohorts. Data is reported according to the frequency of magrolimab administered: QW, Q2W, QW to Q2W for both TN/U AML and TN MDS cohorts.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=29 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=42 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=9 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=24 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=56 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=14 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C2D1 Predose
|
398.05 ug/mL
Standard Deviation 251.639
|
408.84 ug/mL
Standard Deviation 216.656
|
390.50 ug/mL
Standard Deviation 104.538
|
480.74 ug/mL
Standard Deviation 206.793
|
487.42 ug/mL
Standard Deviation 205.862
|
496.57 ug/mL
Standard Deviation 179.237
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C2D1 1 hour
|
807.67 ug/mL
Standard Deviation 419.553
|
919.33 ug/mL
Standard Deviation 313.966
|
948.50 ug/mL
Standard Deviation 88.695
|
1009.00 ug/mL
Standard Deviation 333.772
|
1078.64 ug/mL
Standard Deviation 332.665
|
1064.00 ug/mL
Standard Deviation 216.115
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C2D2 Predose
|
0.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C2D3 Predose
|
0.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C2D4 Predose
|
0.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C2D4 1 hour
|
1.09 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C2D8 Predose
|
440.64 ug/mL
Standard Deviation 274.761
|
528.31 ug/mL
Standard Deviation 244.068
|
458.63 ug/mL
Standard Deviation 156.315
|
554.06 ug/mL
Standard Deviation 228.605
|
573.62 ug/mL
Standard Deviation 213.474
|
491.43 ug/mL
Standard Deviation 167.348
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C2D15 Predose
|
294.00 ug/mL
Standard Deviation 213.546
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C2D22 Predose
|
325.50 ug/mL
Standard Deviation 178.898
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C3D1 Predose
|
494.00 ug/mL
Standard Deviation 222.682
|
549.52 ug/mL
Standard Deviation 260.353
|
507.50 ug/mL
Standard Deviation 188.883
|
631.87 ug/mL
Standard Deviation 216.160
|
597.71 ug/mL
Standard Deviation 324.158
|
602.77 ug/mL
Standard Deviation 253.499
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C3D1 1 hour
|
971.76 ug/mL
Standard Deviation 462.426
|
1245.85 ug/mL
Standard Deviation 449.410
|
994.86 ug/mL
Standard Deviation 273.703
|
1306.13 ug/mL
Standard Deviation 396.321
|
1272.23 ug/mL
Standard Deviation 402.487
|
1062.00 ug/mL
Standard Deviation 328.337
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C4D1 Predose
|
336.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C5D1 Predose
|
673.29 ug/mL
Standard Deviation 183.521
|
301.28 ug/mL
Standard Deviation 143.219
|
513.38 ug/mL
Standard Deviation 238.555
|
666.38 ug/mL
Standard Deviation 317.290
|
246.76 ug/mL
Standard Deviation 164.420
|
542.00 ug/mL
Standard Deviation 319.484
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C5D1 1 hour
|
1150.50 ug/mL
Standard Deviation 342.217
|
1063.43 ug/mL
Standard Deviation 445.885
|
1140.78 ug/mL
Standard Deviation 343.685
|
1242.99 ug/mL
Standard Deviation 691.574
|
917.67 ug/mL
Standard Deviation 318.951
|
1104.69 ug/mL
Standard Deviation 488.709
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C6D1 Predose
|
—
|
—
|
—
|
850.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C7D1 Predose
|
781.83 ug/mL
Standard Deviation 256.528
|
274.20 ug/mL
Standard Deviation 148.275
|
629.56 ug/mL
Standard Deviation 268.028
|
628.00 ug/mL
Standard Deviation 504.250
|
281.01 ug/mL
Standard Deviation 190.602
|
495.76 ug/mL
Standard Deviation 352.143
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C7D1 1 hour
|
1243.17 ug/mL
Standard Deviation 344.023
|
932.50 ug/mL
Standard Deviation 270.978
|
1297.50 ug/mL
Standard Deviation 310.962
|
1325.33 ug/mL
Standard Deviation 673.298
|
1007.87 ug/mL
Standard Deviation 365.807
|
1039.36 ug/mL
Standard Deviation 312.776
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C9D1 Predose
|
584.00 ug/mL
Standard Deviation 318.198
|
250.71 ug/mL
Standard Deviation 122.473
|
522.56 ug/mL
Standard Deviation 266.403
|
712.50 ug/mL
Standard Deviation 689.429
|
339.06 ug/mL
Standard Deviation 170.950
|
401.78 ug/mL
Standard Deviation 283.485
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C9D1 1 hour
|
1290.00 ug/mL
Standard Deviation 608.112
|
772.50 ug/mL
Standard Deviation 296.855
|
1146.88 ug/mL
Standard Deviation 304.099
|
1170.50 ug/mL
Standard Deviation 635.689
|
1218.19 ug/mL
Standard Deviation 245.934
|
1036.63 ug/mL
Standard Deviation 313.181
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C11D1 Predose
|
—
|
172.40 ug/mL
Standard Deviation 111.157
|
422.29 ug/mL
Standard Deviation 315.174
|
—
|
511.27 ug/mL
Standard Deviation 360.621
|
545.81 ug/mL
Standard Deviation 332.891
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C11D1 1 hour
|
—
|
542.50 ug/mL
Standard Deviation 365.574
|
988.63 ug/mL
Standard Deviation 372.345
|
—
|
1367.50 ug/mL
Standard Deviation 343.182
|
1352.83 ug/mL
Standard Deviation 389.004
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C13D1 Predose
|
—
|
349.50 ug/mL
Standard Deviation 204.719
|
422.00 ug/mL
Standard Deviation 174.360
|
—
|
370.75 ug/mL
Standard Deviation 138.914
|
291.67 ug/mL
Standard Deviation 177.293
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C13D1 1 hour
|
—
|
998.25 ug/mL
Standard Deviation 111.870
|
1210.00 ug/mL
Standard Deviation 223.756
|
—
|
1212.88 ug/mL
Standard Deviation 531.496
|
968.20 ug/mL
Standard Deviation 249.544
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C15D1 Predose
|
—
|
—
|
443.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
End of Treatment (EOT, Up to 4 years)
|
298.96 ug/mL
Standard Deviation 203.651
|
231.47 ug/mL
Standard Deviation 203.912
|
290.82 ug/mL
Standard Deviation 138.712
|
611.91 ug/mL
Standard Deviation 411.501
|
311.15 ug/mL
Standard Deviation 307.602
|
288.39 ug/mL
Standard Deviation 184.303
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
Safety Follow-up (FU, Up to 4 years plus 30 days)
|
29.36 ug/mL
Standard Deviation 33.138
|
78.26 ug/mL
Standard Deviation 90.758
|
152.00 ug/mL
Standard Deviation 57.983
|
235.96 ug/mL
Standard Deviation 189.895
|
106.45 ug/mL
Standard Deviation 198.336
|
32.97 ug/mL
Standard Deviation 44.045
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D1 Predose
|
0.18 ug/mL
Standard Deviation 0.958
|
0.00 ug/mL
Standard Deviation 0.00
|
0.00 ug/mL
Standard Deviation 0.00
|
0.00 ug/mL
Standard Deviation 0.00
|
0.00 ug/mL
Standard Deviation 0.00
|
0.00 ug/mL
Standard Deviation 0.00
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D1 1 hour
|
0.41 ug/mL
Standard Deviation 0.830
|
0.29 ug/mL
Standard Deviation 0.377
|
0.19 ug/mL
Standard Deviation 0.218
|
16.54 ug/mL
Standard Deviation 76.838
|
0.40 ug/mL
Standard Deviation 0.615
|
0.77 ug/mL
Standard Deviation 0.696
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D4 Predose
|
0.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D4 1 hour
|
0.32 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D8 Predose
|
0.00 ug/mL
Standard Deviation 0.00
|
0.07 ug/mL
Standard Deviation 0.398
|
0.00 ug/mL
Standard Deviation 0.00
|
17.39 ug/mL
Standard Deviation 83.188
|
0.00 ug/mL
Standard Deviation 0.00
|
0.00 ug/mL
Standard Deviation 0.00
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D8 1 hour
|
254.58 ug/mL
Standard Deviation 53.242
|
309.17 ug/mL
Standard Deviation 103.697
|
258.43 ug/mL
Standard Deviation 72.514
|
304.36 ug/mL
Standard Deviation 49.765
|
293.09 ug/mL
Standard Deviation 75.213
|
262.54 ug/mL
Standard Deviation 68.001
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D11 Predose
|
38.50 ug/mL
Standard Deviation 4.384
|
0.00 ug/mL
Standard Deviation 0.00
|
—
|
95.70 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
189.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D11 1 hour
|
318.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
338.00 ug/mL
Standard Deviation 0.00
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D15 Predose
|
320.62 ug/mL
Standard Deviation 166.137
|
348.98 ug/mL
Standard Deviation 138.719
|
237.01 ug/mL
Standard Deviation 109.654
|
360.06 ug/mL
Standard Deviation 115.170
|
349.13 ug/mL
Standard Deviation 93.294
|
348.64 ug/mL
Standard Deviation 142.833
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D15 1 hour
|
778.88 ug/mL
Standard Deviation 268.194
|
732.50 ug/mL
Standard Deviation 335.509
|
578.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
1016.75 ug/mL
Standard Deviation 131.801
|
754.00 ug/mL
Standard Deviation 207.456
|
887.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D16 Predose
|
351.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D17 Predose
|
278.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D18 Predose
|
249.00 ug/mL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D22 Predose
|
416.80 ug/mL
Standard Deviation 131.60
|
374.63 ug/mL
Standard Deviation 183.020
|
308.33 ug/mL
Standard Deviation 99.219
|
490.05 ug/mL
Standard Deviation 151.489
|
437.63 ug/mL
Standard Deviation 183.664
|
447.93 ug/mL
Standard Deviation 163.772
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Concentration for Magrolimab in TN/U AML and TN MDS Participants
C1D22 1 hour
|
873.17 ug/mL
Standard Deviation 217.208
|
999.00 ug/mL
Standard Deviation 517.850
|
—
|
1253.33 ug/mL
Standard Deviation 123.423
|
790.00 ug/mL
Standard Deviation 72.187
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: The Immunogenicity Analysis Set included participants in All Enrolled Analysis Set, who took at least 1 dose of magrolimab and have at least 1 anti-drug antibody (ADA) sample result reported.
As per the pre-specified analysis, this outcome measure was analyzed based on different dosing regimens and timepoints when magrolimab was given alone and in combination with the azacitidine. Therefore, the data is reported for magrolimab as monotherapy and magrolimab plus azacitidine. Also, the arms are based on the frequency of magrolimab administered: QW, Q2W, QW to Q2W, Q4W, BIW and BIW to QW as applicable in different cohorts.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=9 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=10 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=5 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=12 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=30 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=48 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
n=9 Participants
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
n=26 Participants
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=56 Participants
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
n=14 Participants
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
n=6 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=4 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
n=11 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
n=16 Participants
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
n=1 Participants
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants Who Developed Anti-Magrolimab Antibodies
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
6.7 percentage of participants
|
4.7 percentage of participants
|
11.1 percentage of participants
|
0 percentage of participants
|
3.9 percentage of participants
|
0 percentage of participants
|
16.7 percentage of participants
|
0 percentage of participants
|
18.2 percentage of participants
|
6.7 percentage of participants
|
0 percentage of participants
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants in the Full Analysis Set with CR were analyzed. For the TN MDS Cohort, only participants with higher MDS risk were included. As per the pre-specified analysis, this outcome measure was applicable only for the all AML and TN MDS cohorts.
For AML participants: The DCR was defined as the time measurement criteria were first met for CR (including morphologic CR, CRMRD-, cytogenetic complete remission (cCR), and molecular complete remission (mCR) until the first date that recurrent disease or death with evidence of no disease recurrence was objectively documented. CR and CRMRD- were defined in outcome measure 2. cCR was defined as complete disappearance of chromosomal abnormality without appearance of new ones. mCR was defined as morphological blast of ≤ 5% and recovery of absolute neutrophil count (ANC), platelets, and hemoglobin from complete blood counts as well as peripheral blast. For MDS participants: The DCR was defined as the time measurement criteria were first met for CR until the first date that recurrent disease or death with evidence of no disease recurrence is objectively documented. Kaplan-Meier (KM) estimates were used in the outcome measure analysis.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=12 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=19 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=28 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Complete Remission (DCR) in Participants With AML and MDS
|
14.4 months
Interval 3.7 to
Upper limit of confidence interval (CI) was not reached due to insufficient number of events.
|
8.5 months
Interval 7.3 to 12.9
|
9.4 months
Interval 5.1 to 11.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants with MDS in the Full Analysis Set with data available were analyzed. For the TN MDS Cohort, only participants with higher risk MDS were included. As per the pre-specified analysis, this outcome measure was applicable only the MDS cohorts.
ORR was the percentage of participants who achieved CR, partial remission (PR), marrow CR or hematological improvement (HI) prior to initiation of a new anticancer therapy including SCT per IWG 2006 criteria per investigator's evaluation. CR was defined in outcome measure 2. PR was defined as all CR criteria if abnormal before treatment except the bone marrow blasts decreased by 50% over pretreatment but still \> 5% and cellularity and morphology not relevant. Marrow CR is defined as bone marrow ≤5% myeloblasts and decrease by ≥50% over pretreatment, stable disease with any hematological improvement, peripheral blood: if hematological improvement responses, they were noted in addition to marrow CR. Stable Disease: Failure to achieve at least PR, but no evidence of progression for \> 8 weeks. Percentages were rounded off.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=17 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=5 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=10 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=9 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
n=5 Participants
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
n=3 Participants
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of MDS Participants With Objective Response Rate (ORR) as Defined by IWG 2006 MDS Response Criteria
|
81.3 percentage of participants
Interval 63.6 to 92.8
|
69.8 percentage of participants
Interval 57.0 to 80.8
|
23.5 percentage of participants
Interval 6.8 to 49.9
|
0.0 percentage of participants
Interval 0.0 to 52.2
|
10.0 percentage of participants
Interval 0.3 to 44.5
|
33.3 percentage of participants
Interval 7.5 to 70.1
|
40.0 percentage of participants
Interval 5.3 to 85.3
|
0.0 percentage of participants
Interval 0.0 to 70.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants in the Full Analysis Set with AML were analyzed. As per the pre-specified analysis, this outcome measure was applicable only for all AML cohorts.
ORR is the percentage of participants who achieve CR, CR with incomplete hematologic (count) recovery (CRi), CR with partial hematologic (count) recovery (CRh), Partial Response (PR), Morphologic Leukemia-Free State (MLFS) prior to initiation of a new anti-cancer therapy including SCT per European Leukemia Net (ELN) AML 2017 recommendations per investigator's evaluation. CR was defined in outcome measure 2. CRi was defined as neutrophils ≥ 1.0 × 10\^9/L or platelets ≥ 100 × 10\^9/L bone marrow blasts \< 5%. Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; MRD positive or unknown. CRh was defined in outcome measure 10. PR was defined in outcome measure 8. MLFS was defined as bone marrow blasts \< 5%. Absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required; marrow should not merely be "aplastic"; at least 200 cells should be enumerated or cellularity should be at least 10%.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=87 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=19 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=6 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=1 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of AML Participants With Objective Response Rate (ORR)
|
47.1 percentage of participants
Interval 36.3 to 58.1
|
21.1 percentage of participants
Interval 6.1 to 45.6
|
16.7 percentage of participants
Interval 0.4 to 64.1
|
0.0 percentage of participants
Interval 0.0 to 97.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants in the Full Analysis Set with AML were analyzed. As per the pre-specified analysis, this outcome measure was applicable only for all AML cohorts.
CRh was defined as CR with partial platelet and absolute neutrophil count recovery while on study prior to initiation of any new anti-acute myeloid leukemia (AML) therapy or stem cell transplant (SCT).
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=87 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=19 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=6 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=1 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh) for AML Participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants in the Full Analysis Set with AML who achieved ORR were analyzed. As per the pre-specified analysis, this outcome measure was applicable only for the AML cohorts.
The DOR was defined as time measurement criteria were met for complete remission (CR) (including morphologic CR, CRMRD-, cytogenetic complete remission (cCR), and molecular complete remission (mCR), incomplete blood count recovery (CRi), partial hematologic recovery (CRh), partial remission (PR), marrow CR, or morphologic leukemia-free state (MLFS), whichever was first recorded, until the first date that recurrent or progressive disease, or death with evidence of no disease magrolimab progression is objectively documented. CR and CRMRD- were defined in outcome measure 2. cCR and mCR were defined in outcome measure 7. Marrow CR and PR were defined in outcome measure 8. CRi and MLFS were defined in outcome measure 9. CRh was defined in outcome measure 10. KM estimates were used in the outcome measure analysis.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=41 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=4 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=1 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=1 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Response (DOR) for Participants With AML
|
8.7 months
Interval 7.4 to 10.4
|
2.7 months
Interval 0.7 to
Upper limit of CI was not reached due to insufficient number of events.
|
2.1 months
Lower and upper limit of CI were not reached due to insufficient number of events.
|
NA months
Median, lower and upper limit of CI were not reached due to insufficient number of events.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants in the Full Analysis Set with TN MDS who achieved ORR were analyzed. For the TN MDS Cohort, only participants with higher MDS risk were included. As per the pre-specified analysis, this outcome measure was applicable for only TN MDS cohorts.
The DOR was measured from the time measurement criteria were first met for objective response as assessed by IWG MDS criteria until the first date that recurrent disease or death with evidence of no disease recurrence is objectively documented. KM estimates were used in the outcome measure analysis.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=26 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=44 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Response for Participants With MDS
|
12.9 months
Interval 7.6 to
Upper limit of CI was not reached due to insufficient number of events.
|
9.5 months
Interval 7.9 to 12.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants in the Full Analysis Set were analyzed. For the TN MDS Cohort, only participants with higher MDS risk were included.
The length of overall survival will be measured from the date of study treatment initiation until the date of death from any cause. KM estimates were used in the outcome measure analysis.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=87 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=19 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=6 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=1 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
n=17 Participants
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
n=5 Participants
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=10 Participants
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
n=9 Participants
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
n=5 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=3 Participants
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Survival (OS) for Participants With AML or MDS
|
NA months
Interval 17.7 to
Median and upper limit of CI were not reached due to insufficient number of events.
|
19.4 months
Interval 13.4 to 24.7
|
10.8 months
Interval 7.2 to 12.8
|
5.2 months
Interval 1.4 to 9.9
|
8.5 months
Interval 4.5 to
Upper limit of CI was not reached due to insufficient number of events.
|
33.6 months
Lower and upper limit of CI were not reached due to insufficient number of events.
|
8.5 months
Interval 3.7 to 14.7
|
14.1 months
Interval 7.8 to
Upper limit of CI was not reached due to insufficient number of events.
|
4.2 months
Interval 2.3 to
Upper limit of CI was not reached due to insufficient number of events.
|
NA months
Interval 0.6 to
Median and upper limit of CI were not reached due to insufficient number of events.
|
NA months
Interval 3.5 to
Median and upper limit of CI were not reached due to insufficient number of events.
|
30.6 months
Interval 30.6 to
Upper limit of CI was not reached due to insufficient number of events.
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants in the Full Analysis Set were analyzed. For the TN MDS Cohort, only participants with higher MDS risk were included. As per the pre-specified analysis, this outcome measure was applicable only for all AML and TN MDS cohorts. KM estimates were used in the outcome measure analysis.
The length of PFS is defined as the time from the date of study treatment initiation until the date of documented disease progression (PD) or death from any cause, whichever occurs first. PD for MDS: \<5% blasts: if blasts increase ≥50% to \>5%; 5%-10% blasts: if blasts increase ≥50% to \>10%; 10%-20% blasts: if blasts increase ≥50% to \>20%; 20%-30% blasts: if blasts increase ≥50% to \>30%. Participants with at least 50% decrement from maximum remission/response in granulocytes / platelets or reduction in Hgb by ≥ 2 g/dL or transfusion dependence. PD for AML was defined as any evidence for an increase in bone marrow blast percentage and/or increase of absolute blast counts in the blood: \> 50% increase in marrow blasts over baseline (a minimum 15% point increase is required in cases with \< 30% blasts at baseline; or persistent marrow blast percentage of \>70% over at least 3 months; without at least a 100% improvement in absolute neutrophil count.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=87 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=19 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=6 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=1 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Progression Free Survival (PFS) for Participants With AML or MDS
|
14.0 months
Interval 8.6 to 20.4
|
10.7 months
Interval 7.6 to 11.8
|
7.3 months
Interval 4.4 to 9.7
|
2.6 months
Interval 1.0 to 6.0
|
5.2 months
Interval 0.9 to
Upper limit of CI was not reached due to insufficient number of events.
|
1.9 months
Lower and upper limit of CI were not reached due to insufficient number of events.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants in the Full Analysis Set with CR were analyzed. For the TN MDS Cohort, only participants with higher MDS risk were included. As per the pre-specified analysis, this outcome measure was applicable only for the all AML and TN MDS cohorts.
The length of RFS is defined from the first date of attaining a CR (including morphologic CR, CRMRD-, cCR, and mCR) until the date of AML relapse or death from any cause, whichever occurs first.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=12 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=19 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=28 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Relapse Free Survival (RFS) for Participants With AML or MDS
|
14.4 months
Interval 3.7 to
Upper limit of confidence interval (CI) was not reached due to insufficient number of participants with events.
|
8.5 months
Interval 7.3 to 12.9
|
9.4 months
Interval 5.1 to 11.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants in the Full Analysis Set were analyzed. For the TN MDS Cohort, only participants with higher MDS risk were included. As per the pre-specified analysis, this outcome measure was applicable only for all AML and TN MDS cohorts.
For AML, EFS was defined as the time from the date of study treatment initiation until the date of documented disease progression, death from any cause, or treatment failure (defined as failure to achieve CR/CRi/CRh by Cycle 5 Day 1), whichever occurred first. CR/CRi/CRh were defined in outcome measures 2, 9 and 10 respectively. For MDS, EFS was defined as the time from the date of study treatment initiation to transformation to AML or death from any cause, whichever occurred first. Participants who were not observed to have one of these events during the study were censored at their last response assessment date with evidence of no transformation to AML. KM estimates were used in the outcome measure analysis.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=87 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=19 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=6 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=1 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Event Free Survival (EFS) for Participants With AML or MDS
|
18.2 months
Interval 12.9 to
Upper limit of CI were not reached due to insufficient number of events.
|
23.1 months
Interval 11.8 to
Upper limit of CI were not reached due to insufficient number of events.
|
3.7 months
Interval 2.1 to 7.3
|
1.7 months
Interval 0.8 to 3.5
|
1.4 months
Interval 0.0 to
Upper limit of CI were not reached due to insufficient number of events.
|
1.9 months
Lower and upper limit of CI were not reached due to insufficient number of events.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline and Day 1Population: Participants in the Safety Analysis Set were analyzed. For the TN MDS Cohort, only participants with higher MDS risk were included. As per the pre-specified analysis, this outcome measure was applicable only for the R/R AML and TN MDS cohorts.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=1 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=87 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=19 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=6 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
n=1 Participants
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Hemoglobin on Therapy
Change at Day 1
|
-0.1 g/dL
Standard Deviation 1.23
|
-0.7 g/dL
Standard Deviation 1.10
|
-0.7 g/dL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
-0.8 g/dL
Standard Deviation 1.08
|
-0.9 g/dL
Standard Deviation 0.92
|
-1.3 g/dL
Standard Deviation 1.32
|
0.1 g/dL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Hemoglobin on Therapy
Baseline
|
8.5 g/dL
Standard Deviation 1.56
|
9.0 g/dL
Standard Deviation 1.50
|
10.1 g/dL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
8.8 g/dL
Standard Deviation 1.27
|
9.1 g/dL
Standard Deviation 1.39
|
10.3 g/dL
Standard Deviation 1.74
|
8.9 g/dL
Standard Deviation NA
Standard deviation cannot be calculated for 1 participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 12 WeeksPopulation: Data was not collected for this outcome measure.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Up to 5 yearsPopulation: Participants in the Full Analysis Set with MDS were analyzed. For the TN MDS Cohort, only participants with higher MDS risk were included. As per the pre-specified analysis, this outcome measure was applicable only for all AML and TN MDS cohorts.
The MRD-negative response rate was defined as the percentage of participants who reach MRD-negative disease status prior to initiation of other new anti-cancer therapy including SCT and achieve a morphologic CR or marrow CR for MDS participants and achieve CR/CRi/CRh/MLFS for AML participants. MRD-negative disease status will be assessed using a multiparameter flow cytometry-based assay performed by a central laboratory. CR/CRi/MLFS/CRh were defined in outcome measures 2, 9, 10 respectively. Marrow CR was defined in outcome measure 8.
Outcome measures
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 Participants
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 Participants
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=87 Participants
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=19 Participants
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=6 Participants
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=1 Participants
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
Low-Risk MDS Cohort: Magrolimab Q4W
Participants received magrolimab 1 mg/kg on Day 1, 30 mg/kg QW for Cycle 1, followed by 60 mg/kg every 4 weeks (Q4W) from Cycle 2 onward. Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab QW
Dosing schedule may be twice weekly (Day 1, 4, 8, 11, 15, 18, 22, and 25), once weekly (Day 1, 8, 15, 22), or in accordance with a modified recommended Phase 2 dose and schedule determined by the Clinical Trial Steering Committee (CTSC).
Participants may receive the same dose level and schedule (i.e., twice weekly) of magrolimab monotherapy in each cycle (each cycle was of 28 days) as previously received on the Phase 1 AML study (SCI-CD47-002) or may transition to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Minimal Residual Disease (MRD) Negative Response Rate
|
28.1 percentage of participants
Interval 13.7 to 46.7
|
20.6 percentage of participants
Interval 11.5 to 32.7
|
21.8 percentage of participants
Interval 13.7 to 32.0
|
5.3 percentage of participants
Interval 0.1 to 26.0
|
0.0 percentage of participants
Interval 0.0 to 45.9
|
0.0 percentage of participants
Interval 0.0 to 97.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
TN MDS Cohort Higher Risk QW 30 mg/kg
Serious events: 20 serious events
Other events: 32 other events
Deaths: 12 deaths
TN MDS Cohort Higher Risk Q2W 30 mg/kg
Serious events: 40 serious events
Other events: 60 other events
Deaths: 44 deaths
TN MDS Cohort Low Risk QW 30 mg/kg
Serious events: 0 serious events
Other events: 1 other events
Deaths: 1 deaths
TN/U AML Cohort: Magrolimab + Azacitidine
Serious events: 64 serious events
Other events: 84 other events
Deaths: 72 deaths
R/R AML Cohort: Magrolimab + Azacitidine
Serious events: 17 serious events
Other events: 19 other events
Deaths: 18 deaths
R/R AML Cohort: Magrolimab
Serious events: 4 serious events
Other events: 6 other events
Deaths: 6 deaths
Rollover AML Cohort: Magrolimab
Serious events: 1 serious events
Other events: 1 other events
Deaths: 1 deaths
R/R MDS Cohort: Magrolimab + Azacitidine
Serious events: 12 serious events
Other events: 17 other events
Deaths: 15 deaths
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Serious events: 2 serious events
Other events: 5 other events
Deaths: 3 deaths
R/R MDS Cohort: Magrolimab
Serious events: 7 serious events
Other events: 10 other events
Deaths: 7 deaths
Low Risk MDS Cohort: Magrolimab + Azacitidine
Serious events: 8 serious events
Other events: 9 other events
Deaths: 3 deaths
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
Serious events: 3 serious events
Other events: 5 other events
Deaths: 1 deaths
Low Risk MDS Cohort: Magrolimab
Serious events: 1 serious events
Other events: 3 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 participants at risk
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 participants at risk
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=1 participants at risk
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=87 participants at risk
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=19 participants at risk
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=6 participants at risk
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
n=1 participants at risk
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
n=17 participants at risk
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=5 participants at risk
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
n=10 participants at risk
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
n=9 participants at risk
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=5 participants at risk
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
n=3 participants at risk
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Infections and infestations
Bronchitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Bronchopulmonary aspergillosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Anaemia
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
9.5%
6/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
21.9%
7/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
25.4%
16/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
24.1%
21/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
31.6%
6/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
2/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.5%
4/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Haemolysis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Haemolytic anaemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Red blood cell agglutination
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Splenic infarction
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Cardiac failure acute
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Chronic left ventricular failure
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Dilated cardiomyopathy
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Ear and labyrinth disorders
Vertigo
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Endocrine disorders
Thyroid mass
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Abdominal pain
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Colitis ulcerative
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Enterocutaneous fistula
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Enterovesical fistula
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Gastric antral vascular ectasia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Intestinal pseudo-obstruction
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Mesenteric panniculitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Proctitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Vomiting
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Asthenia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Death
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Disease progression
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Fatigue
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Malaise
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Pyrexia
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Hepatobiliary disorders
Cholecystitis
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Hepatobiliary disorders
Hepatic failure
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Hepatobiliary disorders
Hypertransaminasaemia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Immune system disorders
Haemophagocytic lymphohistiocytosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Abdominal abscess
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Abdominal infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Abscess limb
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Anal abscess
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Anal fistula infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Anorectal infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
9.5%
6/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Cellulitis
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Clostridium bacteraemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Colonic abscess
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Coronavirus infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Covid-19
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Cystitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Device related infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Diverticulitis
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Enterococcal infection
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Enterocolitis infectious
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Escherichia bacteraemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Fungal skin infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Klebsiella bacteraemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Klebsiella infection
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Muscle abscess
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Neutropenic sepsis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Osteomyelitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Periorbital cellulitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Perirectal abscess
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Pneumonia
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
9.5%
6/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.6%
11/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Pneumonia aspiration
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Pneumonia bacterial
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Pneumonia fungal
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
26.3%
5/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Pseudomonas infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Pulmonary sepsis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Respiratory tract infection
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Sepsis
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Septic shock
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Skin infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Soft tissue infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Staphylococcal infection
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Staphylococcal sepsis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Tooth infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Urinary tract infection
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
2/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Vascular device infection
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Wound infection
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Lumbar vertebral fracture
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Transfusion reaction
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Ejection fraction decreased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Platelet count decreased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Sars-cov-2 test positive
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Transaminases increased
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Troponin I increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypervolaemia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.7%
5/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplastic syndrome
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Depressed level of consciousness
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Headache
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Ischaemic stroke
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Seizure
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Syncope
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Confusional state
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.7%
5/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Suicidal ideation
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Haematuria
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Renal amyloidosis
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Renal colic
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Embolism
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Haematoma
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Hypotension
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
Other adverse events
| Measure |
TN MDS Cohort Higher Risk QW 30 mg/kg
n=32 participants at risk
Participants who were treatment-naive (TN) with higher risk myelodysplastic syndrome (MDS) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly (QW) starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Higher Risk Q2W 30 mg/kg
n=63 participants at risk
Participants who were TN with higher risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then weekly starting Cycle 2 and given every 2 weeks (Q2W) from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN MDS Cohort Low Risk QW 30 mg/kg
n=1 participants at risk
Participants who were TN with low risk MDS received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
TN/U AML Cohort: Magrolimab + Azacitidine
n=87 participants at risk
Participants who were treatment-naive or unfit (TN/U) with acute myeloid leukemia (AML) received 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, and then QW starting Cycle 2 and then given QW and Q2W from Cycle 3 up to end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab + Azacitidine
n=19 participants at risk
Participants with relapsed/refractory (r/r) AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/ kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg QW and Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R AML Cohort: Magrolimab
n=6 participants at risk
Participants with r/r AML received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, Day 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Day 11 and Day 15, 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, and 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Rollover AML Cohort: Magrolimab
n=1 participants at risk
Participants received the same dose level and schedule (30 mg/kg, twice weekly) of magrolimab monotherapy as previously received on the Phase 1 AML study (SCI-CD47-002) or transitioned to once-weekly dosing in this study at the discretion of the Investigator in each 28-day cycle and with Sponsor approval. Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab + Azacitidine
n=17 participants at risk
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
R/R MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=5 participants at risk
Participants with r/r MDS received magrolimab 1 mg/kg for Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8, 30 mg/kg on Cycle 1 Days 11, 15 and 22 through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Participants received azacitidine 75 mg/m\^2 on Days 1 to 7 of each cycle (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
R/R MDS Cohort: Magrolimab
n=10 participants at risk
Participants with r/r MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11, 15, 22, through end of Cycle 2 and then 30 mg/kg QW in Cycle 2 and then 30 mg/kg Q2W starting Cycle 3 and thereafter (each cycle was of 28 days). Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab + Azacitidine
n=9 participants at risk
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
|
Low Risk MDS Cohort: Magrolimab to Magrolimab + Azacitidine
n=5 participants at risk
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Participants received azacitidine 75 mg/m\^2 on Days 1 to 5 of each cycle. For participants who could not tolerate 60 mg/kg dose, the dose of magrolimab was reduced to 45 mg/kg. Maximum treatment duration was up to 4 years.
Participants with r/r MDS who did not have an objective response with magrolimab at the first protocol response assessment had azacitidine added to magrolimab for subsequent cycles.
|
Low Risk MDS Cohort: Magrolimab
n=3 participants at risk
Participants with low risk MDS received 1 mg/kg magrolimab on Cycle 1 Week 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15 and 22; 60 mg/kg on Day 1 of Cycle 2 and subsequent cycles (each cycle was of 28 days) (each cycle was of 28 days) up to the end of the study. Maximum treatment duration was up to 4 years.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
General disorders
Oedema peripheral
|
18.8%
6/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.8%
15/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
29.9%
26/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
26.3%
5/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Injection site pruritus
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Injection site reaction
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
8.0%
7/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Localised oedema
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Malaise
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Mucosal inflammation
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Non-cardiac chest pain
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Oedema
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Pain
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Peripheral swelling
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Pyrexia
|
34.4%
11/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.5%
11/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
29.9%
26/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
29.4%
5/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Suprapubic pain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Vaccination site pain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Hepatobiliary disorders
Hepatic lesion
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
8.0%
7/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Abscess limb
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Pericardial effusion
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Acute sinusitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Haematoma
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Bacteraemia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Candida infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Cellulitis
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Clostridium difficile infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Anaemia
|
46.9%
15/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
49.2%
31/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
34.5%
30/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
2/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
47.1%
8/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
60.0%
3/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
4/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
44.4%
4/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
80.0%
4/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Coagulopathy
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Platelet count decreased
|
43.8%
14/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
42.9%
27/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
27.6%
24/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
35.3%
6/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
44.4%
4/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
60.0%
3/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
7/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
26.4%
23/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
42.1%
8/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Troponin T increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Haemolysis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Haemolytic anaemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Neutropenia
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
14.3%
9/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
13.8%
12/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Red blood cell agglutination
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Troponin increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Covid-19
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
14.3%
9/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.1%
14/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
2/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Weight decreased
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
14.3%
9/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
14.9%
13/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
3/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Arrhythmia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Atrial fibrillation
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Depression
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Bradycardia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Cardiac discomfort
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Cardiogenic shock
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Diastolic dysfunction
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Sinus tachycardia
|
12.5%
4/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
9.2%
8/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
29.4%
5/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Supraventricular tachycardia
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Cardiac disorders
Tachycardia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Congenital, familial and genetic disorders
Porokeratosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Ear and labyrinth disorders
Deafness
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.7%
5/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Cataract
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Conjunctival haemorrhage
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Diplopia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Dry eye
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Eye discharge
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Eye haemorrhage
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Eye pruritus
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Eyelid ptosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Periorbital oedema
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Photophobia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Vision blurred
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Visual impairment
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Eye disorders
Vitreous floaters
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Abdominal distension
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.7%
5/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Abdominal pain
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
14/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.0%
20/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
41.2%
7/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Anal incontinence
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Constipation
|
81.2%
26/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
63.5%
40/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
49.4%
43/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
47.4%
9/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
2/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
52.9%
9/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
44.4%
4/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
80.0%
4/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Dental discomfort
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Diarrhoea
|
43.8%
14/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
42.9%
27/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
48.3%
42/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
47.4%
9/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
35.3%
6/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Dry mouth
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
8.0%
7/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Dyspepsia
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.6%
11/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
8.0%
7/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Gingival erythema
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Gingival pain
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Haematochezia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
7.9%
5/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
8.0%
7/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Lip dry
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Mouth ulceration
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Nausea
|
34.4%
11/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
52.4%
33/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
48.3%
42/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
36.8%
7/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
52.9%
9/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
55.6%
5/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Oral blood blister
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Oral disorder
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Oral dysaesthesia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Oral mucosal blistering
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Oral pain
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Rectal lesion
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Stomatitis
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
7.9%
5/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.7%
5/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
50.0%
3/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Toothache
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Gastrointestinal disorders
Vomiting
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
27.0%
17/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
24.1%
21/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
35.3%
6/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Asthenia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.7%
8/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
9.2%
8/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Catheter site bruise
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Catheter site erythema
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Catheter site haemorrhage
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Catheter site pain
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Catheter site rash
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Chest discomfort
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Chest pain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Chills
|
18.8%
6/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
14/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.8%
19/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
35.3%
6/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
60.0%
3/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Complication associated with device
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Cyst
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Face oedema
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Facial pain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Fatigue
|
46.9%
15/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
31.7%
20/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
39.1%
34/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
35.3%
6/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
30.0%
3/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
44.4%
4/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
66.7%
2/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Gait disturbance
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Hypothermia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
General disorders
Influenza like illness
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Device related bacteraemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Escherichia urinary tract infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Gingivitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Influenza
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Localised infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Metapneumovirus infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Oral candidiasis
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Osteomyelitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Otitis externa
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Pneumonia
|
12.5%
4/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
8.0%
7/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Pneumonia bacterial
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Pneumonia fungal
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Sinusitis
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
2/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Soft tissue infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Subcutaneous abscess
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Tooth infection
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Upper respiratory tract infection
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Urinary tract infection
|
12.5%
4/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
7.9%
5/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
8.0%
7/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Vaginal cellulitis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Infections and infestations
Wound infection
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Contusion
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
14.3%
9/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.3%
9/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Corneal abrasion
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Dental restoration failure
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Fall
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
19.0%
12/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
25.3%
22/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
26.3%
5/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
2/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
29.4%
5/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Head injury
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Hyphaema
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.8%
15/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.2%
15/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
47.1%
8/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
30.0%
3/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
44.4%
4/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
60.0%
3/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Patella fracture
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Periorbital haemorrhage
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
7.9%
5/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
9.2%
8/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Subdural haemorrhage
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Transfusion reaction
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Vaccination complication
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Injury, poisoning and procedural complications
Wound
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Activated partial thromboplastin time prolonged
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Alanine aminotransferase increased
|
25.0%
8/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
19.0%
12/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
19.5%
17/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Aspartate aminotransferase decreased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Aspartate aminotransferase increased
|
12.5%
4/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
19.0%
12/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
14.9%
13/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
26.3%
5/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood alkaline phosphatase increased
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood bilirubin decreased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood bilirubin increased
|
34.4%
11/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
36.5%
23/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.0%
20/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.5%
4/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
3/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood cholesterol increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood creatinine decreased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood creatinine increased
|
18.8%
6/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
9.5%
6/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
3/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood fibrinogen decreased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood glucose increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood phosphorus increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood sodium decreased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood test abnormal
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood urea increased
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Blood uric acid increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Brain natriuretic peptide increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Electrocardiogram abnormal
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Fibrin D dimer increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Haptoglobin decreased
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
International normalised ratio increased
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Klebsiella test positive
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Lymphocyte count decreased
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Neutrophil count decreased
|
53.1%
17/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
30.2%
19/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.2%
15/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
3/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
Weight increased
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
White blood cell count decreased
|
46.9%
15/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.8%
15/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.1%
14/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Investigations
White blood cell count increased
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
21.9%
7/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
34.9%
22/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
29/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
3/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Dehydration
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.7%
8/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypermagnesaemia
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypervolaemia
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.3%
9/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.5%
4/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
31.6%
6/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.5%
4/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.7%
5/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
28.1%
9/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.8%
15/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
26.4%
23/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
47.4%
9/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
35.3%
6/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
7/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.3%
9/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
18.8%
6/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.7%
8/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.2%
15/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
26.3%
5/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
25.0%
8/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.5%
11/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
25.3%
22/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
42.1%
8/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
41.2%
7/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Iron overload
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Lactic acidosis
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Malnutrition
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Metabolism and nutrition disorders
Polydipsia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
12.5%
4/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.5%
11/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.1%
14/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
26.3%
5/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.7%
8/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.6%
11/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Deep tissue injury
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Fracture pain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Limb discomfort
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.6%
11/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.5%
4/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
8.0%
7/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.7%
5/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.9%
10/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
14.9%
13/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Aphasia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Brain fog
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Disturbance in attention
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Dizziness
|
21.9%
7/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
25.4%
16/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
27.6%
24/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
2/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
44.4%
4/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Dizziness postural
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Dysgeusia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
7/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Headache
|
28.1%
9/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
34.9%
22/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
24.1%
21/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
31.6%
6/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.5%
4/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
60.0%
3/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Hypoaesthesia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Lethargy
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Memory impairment
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Movement disorder
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Paraesthesia
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Peripheral motor neuropathy
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
7.9%
5/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Restless legs syndrome
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Spinal cord compression
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Syncope
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Tremor
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.7%
5/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Nervous system disorders
Vith nerve paralysis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Agitation
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Anxiety
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.5%
10/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Confusional state
|
12.5%
4/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.6%
11/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Insomnia
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
14.3%
9/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.1%
14/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
17.6%
3/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Post-traumatic stress disorder
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Psychiatric disorders
Restlessness
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Acute kidney injury
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.5%
10/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Chromaturia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Dysuria
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
22.2%
2/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Haematuria
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Nocturia
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Pollakiuria
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Polyuria
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Urinary incontinence
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
8.0%
7/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Renal and urinary disorders
Urinary retention
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.7%
5/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Reproductive system and breast disorders
Vulvovaginal pain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Reproductive system and breast disorders
Vulvovaginal pruritus
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
25.0%
8/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
25.4%
16/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
32.2%
28/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
36.8%
7/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
50.0%
3/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
41.2%
7/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
3/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
34.4%
11/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
34.9%
22/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
24.1%
21/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
31.6%
6/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
41.2%
7/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
30.0%
3/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
3/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
2/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
7.9%
5/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
19.5%
17/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
31.6%
6/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
50.0%
3/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.6%
11/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
7.9%
5/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.3%
9/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
2/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal oedema
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.3%
9/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
21.1%
4/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.5%
4/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal erythema
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal lesion
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.5%
10/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
29.4%
5/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary alveolar haemorrhage
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory acidosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory distress
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Sneezing
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnoea
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
15.8%
3/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
9.4%
3/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.7%
5/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Blister
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Dermal cyst
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Dermatitis bullous
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
7/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
7/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Nail discolouration
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
6.2%
2/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.8%
3/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.3%
4/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
2/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Precancerous skin lesion
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
25.0%
8/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.6%
13/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.5%
10/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
26.3%
5/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Purpura
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
2.3%
2/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
8.0%
7/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.5%
4/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
40.0%
2/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
15.6%
5/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
14.3%
9/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.5%
10/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Skin burning sensation
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Skin discolouration
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
7.9%
5/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Skin necrosis
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.1%
1/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Deep vein thrombosis
|
3.1%
1/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Embolism
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.4%
3/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Flushing
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
3.2%
2/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Haemorrhage
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Hypertension
|
25.0%
8/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
7.9%
5/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
100.0%
1/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
6.9%
6/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.5%
2/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.8%
2/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
10.0%
1/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
11.1%
1/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Hypotension
|
21.9%
7/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
12.7%
8/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
19.5%
17/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
36.8%
7/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
16.7%
1/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
23.5%
4/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
20.0%
1/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
30.0%
3/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
33.3%
1/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Pallor
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
1.6%
1/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
4.6%
4/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.3%
1/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
|
Vascular disorders
Venous thrombosis limb
|
0.00%
0/32 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/63 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/87 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/19 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/6 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/1 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
5.9%
1/17 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/10 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/9 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/5 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
0.00%
0/3 • All-cause mortality: Up to 5 years; Adverse events: Up to 4 years
All-cause mortality: All Enrolled Analysis Set included all participants who were enrolled into the study. Adverse events: Safety Analysis Set included all participants who received ≥ 1 dose of magrolimab.
|
Additional Information
Gilead Clinical Study Information Center
Gilead Sciences
Phone: 1-833-445-3230 (GILEAD-0)
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met: * The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or * The study has been completed at all study sites for at least 2 years.
- Publication restrictions are in place
Restriction type: OTHER